A nurse is teaching a client who has a new prescription for gemfibrozil. Which of the following findings should the nurse instruct the client to report as an adverse effect of the medication?

Gemfibrozil is a fibrate used to treat hypertriglyceridemia by activating peroxisome proliferator-activated receptor-alpha. It reduces very-low-density lipoprotein levels but can cause significant gastrointestinal distress and hepatobiliary complications. A critical risk includes the development of cholelithiasis or myopathy, especially when the medication is administered concurrently with certain other lipid-lowering agents. Rationale: A. Tinnitus, or ringing in the ears, is not a recognized or common adverse effect associated with gemfibrozil therapy. This symptom is more frequently linked to ototoxic medications like aminoglycosides or high-dose aspirin. Patients taking fibrates are not generally monitored for auditory changes as part of the standard safety profile for this drug class. B. A decreased LDL level is a therapeutic goal and expected outcome of lipid-lowering therapy, not an adverse effect. Gemfibrozil is primarily indicated to lower triglycerides and increase HDL, though it may also modestly lower LDL. Reporting a desired clinical improvement would not be necessary in the context of identifying harmful medication reactions. C. Epigastric pain must be reported because gemfibrozil can cause biliary stasis, increasing the risk of gallstones and cholecystitis. It can also cause generalized dyspepsia and, in more severe cases, contribute to pancreatitis. If a client experiences upper abdominal pain, the nurse must assess for potentially serious hepatobiliary or pancreatic complications immediately. D. Weight gain is not a typical side effect of gemfibrozil; in fact, the medication does not significantly impact adipose tissue accumulation. Most gastrointestinal side effects of fibrates involve nausea or abdominal discomfort, which would more likely lead to a decrease in appetite. Unexplained weight gain would require investigation into other metabolic or cardiac etiologies.